Rezolute (RZLT) Competitors $7.24 +0.07 (+0.98%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$7.23 -0.01 (-0.14%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RZLT vs. TARS, OGN, ALVO, CNTA, DNLI, IBRX, AGIO, IDYA, OCUL, and HRMYShould you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Tarsus Pharmaceuticals (TARS), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Rezolute vs. Its Competitors Tarsus Pharmaceuticals Organon & Co. Alvotech Centessa Pharmaceuticals Denali Therapeutics ImmunityBio Agios Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Harmony Biosciences Rezolute (NASDAQ:RZLT) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Do analysts recommend RZLT or TARS? Rezolute presently has a consensus price target of $12.50, suggesting a potential upside of 72.65%. Tarsus Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 15.50%. Given Rezolute's stronger consensus rating and higher possible upside, analysts clearly believe Rezolute is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the media favor RZLT or TARS? In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Rezolute. MarketBeat recorded 9 mentions for Tarsus Pharmaceuticals and 6 mentions for Rezolute. Tarsus Pharmaceuticals' average media sentiment score of 1.43 beat Rezolute's score of 0.87 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RZLT or TARS more profitable? Rezolute has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -31.13%. Tarsus Pharmaceuticals' return on equity of -32.36% beat Rezolute's return on equity.Company Net Margins Return on Equity Return on Assets RezoluteN/A -70.09% -63.08% Tarsus Pharmaceuticals -31.13%-32.36%-21.04% Do insiders and institutionals have more ownership in RZLT or TARS? 83.0% of Rezolute shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 18.4% of Rezolute shares are owned by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, RZLT or TARS? Rezolute has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRezoluteN/AN/A-$68.46M-$1.15-6.30Tarsus Pharmaceuticals$182.95M13.32-$115.55M-$2.33-24.77 Which has more volatility and risk, RZLT or TARS? Rezolute has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. SummaryRezolute beats Tarsus Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Rezolute News Delivered to You Automatically Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RZLT vs. The Competition Export to ExcelMetricRezoluteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$623.76M$3.12B$5.77B$9.75BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-6.3021.1082.3326.60Price / SalesN/A358.23503.83158.37Price / CashN/A43.5325.7028.92Price / Book3.318.1310.876.56Net Income-$68.46M-$53.35M$3.28B$266.04M7 Day Performance0.28%0.73%0.12%-0.89%1 Month Performance22.71%7.76%8.94%4.34%1 Year Performance54.04%11.97%51.33%24.06% Rezolute Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RZLTRezolute3.1491 of 5 stars$7.24+1.0%$12.50+72.7%+54.0%$623.76MN/A-6.3040News CoverageAnalyst ForecastTARSTarsus Pharmaceuticals1.9785 of 5 stars$58.58+0.7%$66.67+13.8%+120.6%$2.47B$182.95M-25.1450Positive NewsOGNOrganon & Co.4.8358 of 5 stars$9.40+2.3%$18.00+91.6%-55.6%$2.45B$6.40B3.494,000ALVOAlvotech3.0009 of 5 stars$8.07+0.2%$14.00+73.5%-30.0%$2.43B$491.98M35.091,032Positive NewsShort Interest ↑CNTACentessa Pharmaceuticals2.7585 of 5 stars$16.79+1.4%$31.50+87.6%+17.9%$2.25B$6.85M-9.38200News CoveragePositive NewsAnalyst ForecastGap UpDNLIDenali Therapeutics4.3304 of 5 stars$15.27-2.4%$33.62+120.1%-39.1%$2.23B$330.53M-5.45430Positive NewsIBRXImmunityBio2.4693 of 5 stars$2.34+0.4%$10.75+359.4%-35.9%$2.21B$14.74M-4.87590AGIOAgios Pharmaceuticals4.3624 of 5 stars$37.71-1.2%$56.33+49.4%-9.2%$2.19B$36.50M3.43390Positive NewsIDYAIDEAYA Biosciences4.4041 of 5 stars$24.55-1.5%$47.10+91.9%-32.4%$2.15B$7M-6.4880News CoveragePositive NewsAnalyst ForecastAnalyst RevisionOCULOcular Therapeutix3.4294 of 5 stars$12.21-2.5%$17.20+40.9%+55.0%$2.12B$63.72M-9.54230HRMYHarmony Biosciences4.3023 of 5 stars$36.89-2.8%$51.00+38.2%+3.2%$2.12B$714.73M11.90200News CoveragePositive News Related Companies and Tools Related Companies TARS Alternatives OGN Alternatives ALVO Alternatives CNTA Alternatives DNLI Alternatives IBRX Alternatives AGIO Alternatives IDYA Alternatives OCUL Alternatives HRMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RZLT) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
